secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0000805928-26-000051
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M
--------------------------------------------------------------------------------

- Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.
- GAAP net loss $19.6M ($0.38/share); adjusted net income $4.1M ($0.07/share) vs adjusted net loss $0.9M in Q1 2025.
- Raises full-year 2026 revenue guidance to at least 20% growth or $270M; expects gross margin 74%-76% and positive free cash flow.
- Closed upsized public offering netting $133.3M; used $69.7M to repay Oberland loan; cash & investments rose to $103.6M.
- Received positive coverage decisions from Cigna and Elevance Health; CMS new Level 3 Nerve Procedure Code boosts Avance reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000051/0000805928-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000051/axgn-20260428.htm
  HTML page:      https://secwatch.observer/filing/0000805928-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer